Search

Your search keyword '"Banerjee, Poulabi"' showing total 160 results
Start Over Author "Banerjee, Poulabi"
160 results on '"Banerjee, Poulabi"'

5. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy

Author

Gaudet, Daniel, primary, Greber-Platzer, Susanne, additional, Reeskamp, Laurens F, additional, Iannuzzo, Gabriella, additional, Rosenson, Robert S, additional, Saheb, Samir, additional, Stefanutti, Claudia, additional, Stroes, Erik, additional, Wiegman, Albert, additional, Turner, Traci, additional, Ali, Shazia, additional, Banerjee, Poulabi, additional, Drewery, Tiera, additional, McGinniss, Jennifer, additional, Waldron, Alpana, additional, George, Richard T, additional, Zhao, Xue-Qiao, additional, Pordy, Robert, additional, Zhao, Jian, additional, Bruckert, Eric, additional, and Raal, Frederick J, additional

Published
2024
Full Text
View/download PDF

6. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Author

Dewey, Frederick E, Gusarova, Viktoria, Dunbar, Richard L, O'Dushlaine, Colm, Schurmann, Claudia, Gottesman, Omri, McCarthy, Shane, Van Hout, Cristopher V, Bruse, Shannon, Dansky, Hayes M, Leader, Joseph B, Murray, Michael F, Ritchie, Marylyn D, Kirchner, H Lester, Habegger, Lukas, Lopez, Alex, Penn, John, Zhao, An, Shao, Weiping, Stahl, Neil, Murphy, Andrew J, Hamon, Sara, Bouzelmat, Aurelie, Zhang, Rick, Shumel, Brad, Pordy, Robert, Gipe, Daniel, Herman, Gary A, Sheu, Wayne HH, Lee, I-Te, Liang, Kae-Woei, Guo, Xiuqing, Rotter, Jerome I, Chen, Yii-Der I, Kraus, William E, Shah, Svati H, Damrauer, Scott, Small, Aeron, Rader, Daniel J, Wulff, Anders Berg, Nordestgaard, Børge G, Tybjærg-Hansen, Anne, van den Hoek, Anita M, Princen, Hans MG, Ledbetter, David H, Carey, David J, Overton, John D, Reid, Jeffrey G, Sasiela, William J, Banerjee, Poulabi, Shuldiner, Alan R, Borecki, Ingrid B, Teslovich, Tanya M, Yancopoulos, George D, Mellis, Scott J, Gromada, Jesper, and Baras, Aris

Subjects
Biomedical and Clinical Sciences, Atherosclerosis, Clinical Research, Genetics, Heart Disease, Human Genome, Heart Disease - Coronary Heart Disease, Cardiovascular, 5.1 Pharmaceuticals, 2.1 Biological and endogenous factors, Good Health and Well Being, Aged, Angiopoietin-Like Protein 3, Angiopoietin-like Proteins, Angiopoietins, Animals, Antibodies, Monoclonal, Cardiovascular Diseases, Coronary Artery Disease, Disease Models, Animal, Dose-Response Relationship, Drug, Double-Blind Method, Dyslipidemias, Female, Humans, Lipid Metabolism, Lipids, Male, Mice, Mice, Inbred Strains, Middle Aged, Mutation, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundLoss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. It is not known whether such variants or therapeutic antagonism of ANGPTL3 are associated with a reduced risk of atherosclerotic cardiovascular disease.MethodsWe sequenced the exons of ANGPTL3 in 58,335 participants in the DiscovEHR human genetics study. We performed tests of association for loss-of-function variants in ANGPTL3 with lipid levels and with coronary artery disease in 13,102 case patients and 40,430 controls from the DiscovEHR study, with follow-up studies involving 23,317 case patients and 107,166 controls from four population studies. We also tested the effects of a human monoclonal antibody, evinacumab, against Angptl3 in dyslipidemic mice and against ANGPTL3 in healthy human volunteers with elevated levels of triglycerides or LDL cholesterol.ResultsIn the DiscovEHR study, participants with heterozygous loss-of-function variants in ANGPTL3 had significantly lower serum levels of triglycerides, HDL cholesterol, and LDL cholesterol than participants without these variants. Loss-of-function variants were found in 0.33% of case patients with coronary artery disease and in 0.45% of controls (adjusted odds ratio, 0.59; 95% confidence interval, 0.41 to 0.85; P=0.004). These results were confirmed in the follow-up studies. In dyslipidemic mice, inhibition of Angptl3 with evinacumab resulted in a greater decrease in atherosclerotic lesion area and necrotic content than a control antibody. In humans, evinacumab caused a dose-dependent placebo-adjusted reduction in fasting triglyceride levels of up to 76% and LDL cholesterol levels of up to 23%.ConclusionsGenetic and therapeutic antagonism of ANGPTL3 in humans and of Angptl3 in mice was associated with decreased levels of all three major lipid fractions and decreased odds of atherosclerotic cardiovascular disease. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT01749878 .).

Published
2017

9. Efficacy of evinacumab by low-density lipoprotein receptor genotype and function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study

Author

Gaudet, Daniel, Greber-Platzer, Susanne, Reeskamp, Laurens, Iannuzzo, Gabriella, Rosenson, Robert, Sahed, Samir, Stefanutti, Claudia, Stroes, Erik, Bruckert, Eric, Waldron, Alpana, Banerjee, Poulabi, George, Richard, Jones, Richard, and Raal, Frederick J.

Published
2024
Full Text
View/download PDF

14. SNPs in putative regulatory regions identified by human mouse comparative sequencing and transcription factor binding site data

Author

Banerjee, Poulabi, Bahlo, Melanie, Schwartz, Jody R., Loots, Gabriela G., Houston, Kathryn A., Dubchak, Inna, Speed, Terence P., and Rubin, Edward M.

Abstract

Genome wide disease association analysis using SNPs is being explored as a method for dissecting complex genetic traits and a vast number of SNPs have been generated for this purpose. As there are cost and throughput limitations of genotyping large numbers of SNPs and statistical issues regarding the large number of dependent tests on the same data set, to make association analysis practical it has been proposed that SNPs should be prioritized based on likely functional importance. The most easily identifiable functional SNPs are coding SNPs (cSNPs) and accordingly cSNPs have been screened in a number of studies. SNPs in gene regulatory sequences embedded in noncoding DNA are another class of SNPs suggested for prioritization due to their predicted quantitative impact on gene expression. The main challenge in evaluating these SNPs, in contrast to cSNPs is a lack of robust algorithms and databases for recognizing regulatory sequences in noncoding DNA. Approaches that have been previously used to delineate noncoding sequences with gene regulatory activity include cross-species sequence comparisons and the search for sequences recognized by transcription factors. We combined these two methods to sift through mouse human genomic sequences to identify putative gene regulatory elements and subsequently localized SNPs within these sequences in a 1 Megabase (Mb) region of human chromosome 5q31, orthologous to mouse chromosome 11 containing the Interleukin cluster.

Published
2002

15. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial

Author

Damask, Amy, Steg, P. Gabriel, Schwartz, Gregory G., Szarek, Michael, Hagström, Emil, Badimon, Lina, Chapman, M. John, Boileau, Catherine, Tsimikas, Sotirios, Ginsberg, Henry N., Banerjee, Poulabi, Manvelian, Garen, Pordy, Robert, Hess, Sibylle, Overton, John D., Lotta, Luca A., Yancopoulos, George D., Abecasis, Goncalo R., Baras, Aris, and Paulding, Charles

Published
2020
Full Text
View/download PDF

20. Abstract 16875: Functional Analysis of Low Density Lipoprotein Receptor Variants in Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of Low Density Lipoprotein Receptor Activity

Author

Banerjee, Poulabi, Ali, Shazia, Tarabocchia, Michel, Bouzelmat, Aurelie, Alves, Ana Catarina Dos Santos, Etxebarria, Aitor, Benito-Vicente, Asior, Bourbon, Mafalda, Pordy, Robert, Gipe, Daniel, Gaudet, Daniel, and Martin, César

Published
2017

25. Application of pooled genotyping to scan candidate regions for association with HDL cholesterol levels

Author

Hinds David A, Seymour Albert B, Durham L Kathryn, Banerjee Poulabi, Ballinger Dennis G, Milos Patrice M, Cox David R, Thompson John F, and Frazer Kelly A

Subjects
association study, HDL cholesterol, CETP, SNPs, pooled genotyping, haplotypes, Medicine, Genetics, QH426-470
Abstract

Abstract Association studies are used to identify genetic determinants of complex human traits of medical interest. With the large number of validated single nucleotide polymorphisms (SNPs) currently available, two limiting factors in association studies are genotyping capability and costs. Pooled DNA genotyping has been proposed as an efficient means of screening SNPs for allele frequency differences in case-control studies and for prioritising them for subsequent individual genotyping analysis. Here, we apply quantitative pooled genotyping followed by individual genotyping and replication to identify associations with human serum high-density lipoprotein (HDL) cholesterol levels. The DNA from individuals with low and high HDL cholesterol levels was pooled separately, each pool was amplified by polymerase chain reaction in triplicate and each amplified product was separately hybridised to a high-density oligonucleotide array. Allele frequency differences between case and control groups with low and high HDL cholesterol levels were estimated for 7,283 SNPs distributed across 71 candidate gene regions spanning a total of 17.1 megabases. A novel method was developed to take advantage of independently derived haplotype map information to improve the pooled estimates of allele frequency differences. A subset of SNPs with the largest estimated allele frequency differences between low and high HDL cholesterol groups was chosen for individual genotyping in the study population, as well as in a separate replication population. Four SNPs in a single haplotype block within the cholesteryl ester transfer protein (CETP) gene interval were significantly associated with HDL cholesterol levels in both populations. Our study is among the first to demonstrate the application of pooled genotyping followed by confirmation with individual genotyping to identify genetic determinants of a complex trait.

Published
2004
Full Text
View/download PDF

26. Abstract 12066: The Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Author

Raal, Frederick J, primary, Rosenson, Robert S, additional, Reeskamp, Rens, additional, Kastelein, John J, additional, Rubba, Paolo, additional, Duell, Bart, additional, Koseki, Masahiro, additional, Stroes, Erik S, additional, Ali, Shazia, additional, Banerjee, Poulabi, additional, Chan, KuoChen, additional, Khilla, Nagwa, additional, McGinniss, Jennifer, additional, Pordy, Robert, additional, Zhang, Yi, additional, and Gaudet, Daniel, additional

Published
2021
Full Text
View/download PDF

27. Abstract 12756: Long-Term Efficacy and Safety of Evinacumab in Adult and Adolescent Patients With Homozygous Familial Hypercholesterolemia

Author

Gaudet, Daniel, primary, saheb, samir, additional, Iannuzzo, Gabriella, additional, STEFANUTTI, Claudia, additional, Stroes, Erik S, additional, Rosenson, Robert S, additional, Turner, Traci, additional, ali, shazia, additional, Banerjee, Poulabi, additional, Drewery, Tiera, additional, pordy, robert, additional, Zhao, Jian, additional, and Raal, Frederick J, additional

Published
2021
Full Text
View/download PDF

29. Abstract 12027: Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia Who Participated in Sequential Studies of Alirocumab and Evinacumab

Author

Raal, Frederick J, primary, Rosenson, Robert S, additional, Kolovou, Genovefa, additional, Harada-shiba, Mariko, additional, Mitchenko, Olena, additional, Rubba, Paolo, additional, ali, shazia, additional, Banerjee, Poulabi, additional, Khilla, Nagwa, additional, McGinniss, Jennifer, additional, pordy, robert, additional, and Blom, Dirk J, additional

Published
2021
Full Text
View/download PDF

30. The effect of evinacumab on LDL-C goal attainment in patients with homozygous familial hypercholesterolemia

Author

Raal, Frederick J., primary, Rosenson, Robert, additional, Reeskamp, Laurens, additional, Hovingh, G. Kees, additional, Kastelein, John, additional, Rubba, Paolo, additional, Ali, Shazia, additional, Banerjee, Poulabi, additional, Chan, Kuo-Chen, additional, Khilla, Nagwa, additional, McGinniss, Jennifer, additional, Pordy, Robert, additional, Zhang, Yi, additional, and Gaudet, Daniel, additional

Published
2021
Full Text
View/download PDF

32. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial

Author

Blom, Dirk J., Harada-Shiba, Mariko, Rubba, Paolo, Gaudet, Daniel, Kastelein, John J. P., Charng, Min-Ji, Pordy, Robert, Donahue, Stephen, Ali, Shazia, Dong, Yuping, Khilla, Nagwa, Banerjee, Poulabi, Baccara-Dinet, Marie, Rosenson, Robert S., ACS - Atherosclerosis & ischemic syndromes, Vascular Medicine, and ACS - Pulmonary hypertension & thrombosis

Subjects
low-density lipoprotein, lipoprotein(a), proprotein convertase subtilisin/kexin type 9 inhibitor, lipids (amino acids, peptides, and proteins), homozygous familial hypercholesterolemia
Abstract

Background: Homozygous familial hypercholesterolemia (HoFH) is characterized by extremely elevated low-density lipoprotein–cholesterol (LDL-C) levels and early onset atherosclerotic cardiovascular disease despite treatment with conventional lipid-lowering treatment. Objectives: This study was designed to assess LDL-C reduction with the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in adult patients with HoFH. Methods: This randomized, double-blind, placebo-controlled, parallel-group, phase 3 study evaluated efficacy and safety of alirocumab 150 mg every 2 weeks. The primary endpoint was percent reduction from baseline in LDL-C versus placebo after 12 weeks of treatment. Results: Patients (N = 69) were randomized 2:1 to alirocumab or placebo. At baseline, background lipid-lowering treatment included 67 patients receiving statin (59 patients on high-intensity statin); 50 patients on ezetimibe; 10 patients on lomitapide; and 10 patients undergoing apheresis. Mean baseline LDL-C was 259.6 mg/dl in the placebo group and 295.0 mg/dl in the alirocumab group. At week 12, the least squares mean difference in LDL-C percent change from baseline was −35.6% (alirocumab [−26.9%] vs. placebo [8.6%]; p < 0.0001). Reductions (least squares mean difference) in other atherogenic lipids at week 12 were: apolipoprotein B, −29.8%; non–high-density lipoprotein cholesterol, −32.9%; total cholesterol, −26.5%; and lipoprotein(a), −28.4% (all p < 0.0001). No serious adverse events, permanent treatment discontinuations, or deaths due to treatment-emergent adverse events were reported during the double-blind treatment period. Conclusions: In the largest randomized controlled interventional trial in HoFH patients to date, alirocumab resulted in significant and clinically meaningful reductions in LDL-C at week 12. Alirocumab was generally well tolerated, with a safety profile comparable to that of placebo. (Study in Participants With Homozygous Familial Hypercholesterolemia [HoFH] [ODYSSEY HoFH] NCT03156621.)

Published
2020

37. Corrigendum to “Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia” J Clin Lipidol 11 (2017) 1338-1346

Author

Defesche, Joep C., primary, Stefanutti, Claudia, additional, Langslet, Gisle, additional, Hopkins, Paul N., additional, Seiz, Werner, additional, Baccara-Dinet, Marie T., additional, Hamon, Sara C., additional, Banerjee, Poulabi, additional, and Kastelein, John J.P., additional

Published
2020
Full Text
View/download PDF

38. Evinacumab for Homozygous Familial Hypercholesterolemia

Author

Raal, Frederick J., primary, Rosenson, Robert S., additional, Reeskamp, Laurens F., additional, Hovingh, G. Kees, additional, Kastelein, John J.P., additional, Rubba, Paolo, additional, Ali, Shazia, additional, Banerjee, Poulabi, additional, Chan, Kuo-Chen, additional, Gipe, Daniel A., additional, Khilla, Nagwa, additional, Pordy, Robert, additional, Weinreich, David M., additional, Yancopoulos, George D., additional, Zhang, Yi, additional, and Gaudet, Daniel, additional

Published
2020
Full Text
View/download PDF

39. The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolemia Patients with Little to No Low-Density Lipoprotein Receptor Activity

Author

Rosenson, Robert, primary, Raal, Frederick, additional, Reeskamp, Laurens, additional, Kastelein, John, additional, Baum, Seth, additional, Ali, Shazia, additional, Banerjee, Poulabi, additional, Chan, Kuo-Chen, additional, Gipe, Daniel, additional, Pordy, Robert, additional, and Gaudet, Daniel, additional

Published
2020
Full Text
View/download PDF

41. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity

Author

Bioquímica y biología molecular, Biokimika eta biologia molekularra, Banerjee, Poulabi, Chan, Kuo-Chen, Tarabocchia, Michel, Benito Vicente, Asier, Alves, Ana C., Belloso Uribe, Kepa, Bourbon, Mafalda, Skiba, Paul J., Pordy, Robert, Gipe, Daniel A., Gaudet, Daniel, Martín Plágaro, César Augusto, Bioquímica y biología molecular, Biokimika eta biologia molekularra, Banerjee, Poulabi, Chan, Kuo-Chen, Tarabocchia, Michel, Benito Vicente, Asier, Alves, Ana C., Belloso Uribe, Kepa, Bourbon, Mafalda, Skiba, Paul J., Pordy, Robert, Gipe, Daniel A., Gaudet, Daniel, and Martín Plágaro, César Augusto

Abstract

Objective: Homozygous familial hypercholesterolemia is a rare disease usually caused by LDLR (low-density lipoprotein receptor) mutations. Homozygous familial hypercholesterolemia is characterized by markedly elevated LDL-C (low-density lipoprotein cholesterol) levels and an extremely high risk of premature atherosclerotic cardiovascular disease. A phase 2, proof-of-concept study (NCT02265952) demonstrated that evinacumab, a fully human monoclonal antibody to ANGPTL3 (angiopoietin-like 3 protein), reduced LDL-C levels in 9 patients with genotypically confirmed homozygous familial hypercholesterolemia and was well tolerated. The aim of this study was to analyze the effects of evinacumab on LDLR activity in lymphocytes purified from patients in the proof-of-concept study. Approach and Results: LDLR activity was assessed in patient lymphocytes before and after treatment with evinacumab and versus lymphocytes carrying wild-type LDLR, and also in an LDLR-defective Chinese hamster ovary cell line (CHO-ldlA7) transfected with plasmids encoding the LDLR variants. Overall mean peak reduction in LDL-C with evinacumab was -58 +/- 18%, occurring between Week 4 and Week 12. Mutations identified in the 9 patients were shown to be pathogenic, with loss of LDLR activity versus wild type. Two of the LDLR variants, p.(Cys681*) and p.(Ala627Profs*38), were class 2 type mutations that are retained in the endoplasmic reticulum. Six variants were class 3 type mutations with impaired LDL-C binding activity: p.(Trp87Gly), occurring in 2 patients, p.(Gln254Pro), p.(Ser177Leu), p.(Gly335Val), and p.(Ser306Leu). Evinacumab had no effect on LDLR activity. Conclusions: These results suggest that evinacumab is effective for lowering LDL-C in patients with homozygous familial hypercholesterolemia, and the inhibition of ANGPTL3 in humans lowers LDL-C in a mechanism independent of the LDLR.

Published
2019

43. ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia

Author

Gaudet, Daniel, primary, Gipe, Daniel A., additional, Pordy, Robert, additional, Ahmad, Zahid, additional, Cuchel, Marina, additional, Shah, Prediman K., additional, Chyu, Kuang-Yuh, additional, Sasiela, William J., additional, Chan, Kuo-Chen, additional, Brisson, Diane, additional, Khoury, Etienne, additional, Banerjee, Poulabi, additional, Gusarova, Viktoria, additional, Gromada, Jesper, additional, Stahl, Neil, additional, Yancopoulos, George D., additional, and Hovingh, G. Kees, additional

Published
2017
Full Text
View/download PDF

44. A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics

Author

Ming, Jeffrey E, primary, Abrams, Ruth E, additional, Bartlett, Derek W, additional, Tao, Mengdi, additional, Nguyen, Tu, additional, Surks, Howard, additional, Kudrycki, Katherine, additional, Kadambi, Ananth, additional, Friedrich, Christina M, additional, Djebli, Nassim, additional, Goebel, Britta, additional, Koszycki, Alex, additional, Varshnaya, Meera, additional, Elassal, Joseph, additional, Banerjee, Poulabi, additional, Sasiela, William J, additional, Reed, Michael J, additional, Barrett, Jeffrey S, additional, and Azer, Karim, additional

Published
2017
Full Text
View/download PDF

46. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo

Author

Toth, Peter P., primary, Hamon, Sara C., additional, Jones, Steven R., additional, Martin, Seth S., additional, Joshi, Parag H., additional, Kulkarni, Krishnaji R., additional, Banerjee, Poulabi, additional, Hanotin, Corinne, additional, Roth, Eli M., additional, and McKenney, James M., additional

Published
2016
Full Text
View/download PDF

48. EFFECTS OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ON LIPOPROTEIN PARTICLE CONCENTRATIONS DETERMINED BY NUCLEAR MAGNETIC RESONANCE: SUBSTUDY OF A RANDOMIZED DOUBLE-BLIND PHASE II CLINICAL TRIAL

Author

Koren, Michael J., primary, Kereiakes, Dean, additional, Pourfarzib, Ray, additional, Winegar, Deborah, additional, Banerjee, Poulabi, additional, Hamon, Sara, additional, Hanotin, Corinne, additional, and McKenney, James M., additional

Published
2014
Full Text
View/download PDF

50. TULP1 mutation in two extended Dominican kindreds with autosomal recessive Retinitis pigmentosa

Author

Banerjee, Poulabi, primary, Kleyn, Patrick W., additional, Knowles, James A., additional, Lewis, Charles A., additional, Ross, Barbara M., additional, Parano, Enrico, additional, Kovats, Steve G., additional, Lee, John J., additional, Penchaszadeh, Graciela K., additional, Ott, Jürg, additional, Jacobson, Samuel G., additional, and Gilliam, T. Conrad, additional

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results